|
SRRT expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.01799999985275E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.59530000001895E-06 |
| Normal-vs-Stage2 |
2.187900E-04 |
| Normal-vs-Stage3 |
1.85170000444046E-08 |
| Normal-vs-Stage4 |
2.49780000000088E-05 |
| Stage1-vs-Stage2 |
7.459200E-01 |
| Stage1-vs-Stage3 |
4.062200E-02 |
| Stage1-vs-Stage4 |
3.313000E-01 |
| Stage2-vs-Stage3 |
2.874400E-01 |
| Stage2-vs-Stage4 |
6.395800E-01 |
| Stage3-vs-Stage4 |
6.170800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.00719999954302E-07 |
| Normal-vs-AfricanAmerican |
2.715300E-03 |
| Normal-vs-Asian |
4.240200E-02 |
| Caucasian-vs-AfricanAmerican |
6.843800E-01 |
| Caucasian-vs-Asian |
1.487900E-02 |
| AfricanAmerican-vs-Asian |
2.007600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.94700000034321E-07 |
| Normal-vs-Female |
2.23739999971606E-07 |
| Male-vs-Female |
5.672600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.71739999998977E-06 |
| Normal-vs-Age(41-60Yrs) |
2.33579999997513E-06 |
| Normal-vs-Age(61-80Yrs) |
1.76479999947077E-07 |
| Normal-vs-Age(81-100Yrs) |
8.376900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.774400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.637500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.221200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.254000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.201400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.753400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.42359999636355E-08 |
| Classical-VS-Follicular |
6.778400E-03 |
| Classical-VS-Other |
4.067200E-01 |
| Classical-VS-Normal |
2.04139999999686E-05 |
| Tall-VS-Follicular |
3.456100E-02 |
| Tall-VS-Other |
3.640600E-01 |
| Tall-VS-Normal |
2.32702745961433E-12 |
| Follicular-VS-Other |
8.237400E-01 |
| Follicular-VS-Normal |
1.33999999984979E-07 |
| Other-VS-Normal |
2.181600E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.97090000000999E-06 |
| Normal-vs-N1 |
7.58730000000041E-05 |
| N0-vs-N1 |
7.788200E-01 |
|
|
